American Renal Associates Holdings, Inc (NYSE:ARA) issued its quarterly earnings data on Tuesday, August 8th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.04, Briefing.com reports. American Renal Associates Holdings had a negative net margin of 1.54% and a positive return on equity of 18.25%. The company had revenue of $185.99 million during the quarter, compared to the consensus estimate of $188.23 million. The company’s quarterly revenue was up .2% compared to the same quarter last year.

American Renal Associates Holdings (NYSE:ARA) remained flat at $14.10 during trading on Friday. 351,149 shares of the stock were exchanged. American Renal Associates Holdings has a 12 month low of $13.74 and a 12 month high of $25.42. The firm’s 50-day moving average price is $16.79 and its 200 day moving average price is $17.94. The firm’s market capitalization is $441.12 million.

COPYRIGHT VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/19/american-renal-associates-holdings-inc-nyseara-issues-earnings-results-beats-expectations-by-0-04-eps-updated.html.

An institutional investor recently raised its position in American Renal Associates Holdings stock. The Manufacturers Life Insurance Company increased its stake in American Renal Associates Holdings, Inc (NYSE:ARA) by 19.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,778 shares of the company’s stock after buying an additional 1,443 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in American Renal Associates Holdings were worth $162,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 90.83% of the company’s stock.

ARA has been the subject of several recent research reports. Zacks Investment Research upgraded shares of American Renal Associates Holdings from a “sell” rating to a “hold” rating in a report on Wednesday, May 10th. Wells Fargo & Company upgraded shares of American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. American Renal Associates Holdings currently has a consensus rating of “Buy” and a consensus target price of $25.50.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Earnings History for American Renal Associates Holdings (NYSE:ARA)

Receive News & Stock Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related stocks with our FREE daily email newsletter.